Drug Database
SA

salbutamol (Inspiryl Turbuhaler)

✓ Approved

AstraZeneca UK Limited · ADRB2 · 小分子

什么是 salbutamol?

salbutamol 是一种小分子,由AstraZeneca UK Limited研发。该药已获批,用于治疗相关适应症,给药途径:Inhaled、Topical。

药物档案

商品名Inspiryl Turbuhaler
公司AstraZeneca UK Limited
药物类别小分子
分子靶点ADRB2
给药途径Inhaled, Topical
状态Approved

作用机制

分子靶点

salbutamol 作用于 1 个分子靶点:

ADRB2adrenoceptor beta 2 (B2AR, ARB2)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

salbutamol 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved

相关研究文献

PubMedAnalytical chemistry2026-11-18

Designing of a Test Tube Containing Aptamer-Immobilized Cholesteric Liquid Crystal Network-Based Optical Photonic Sensors for the Multiplex Detection of Doping Substances in Human Blood Serum.

Bashir Manal M, Hussain Saddam S, Cialla-May Dana D, Popp Jürgen J et al.

The detection of doping substances in human serum is a critical concern in both clinical diagnostics and anti-doping efforts. In this study, we present a novel, portable, and cost-effective biosensor system based on cholesteric liquid crystal networks (CLCN) for multiplexed drug detection. The system employs aptamer-immobilized CLCN-based optical sensors, fabricated on flexible polyethylene terephthalate (PET) substrates, for the onsite detection of cocaine, methamphetamine, heroin, tramadol, and salbutamol. The biosensor platform utilizes the unique optical properties of CLCNs, where the helical pitch change in response to analyte binding results in visible color shifts. These sensors are easy to fabricate, as all liquid crystals used are commercially available and inexpensive, making the technology highly accessible. Additionally, the sensors are easy to use, requiring minimal training, and the results can be quickly interpreted via a simple visual readout. The system was evaluated for its performance in spiked human serum samples, demonstrating high sensitivity, specificity, and accuracy in detecting low concentrations of doping substances. The inclusion of QR codes on the sensors allowed for convenient comparison with calibrated reference standards, ensuring reliable results. This biosensor system offers a promising solution for on-site and multiplexed detection of doping substances in human serum, with significant potential for monitoring in clinical and athletic settings.

PMID 43046414
阅读全文 →
PubMedThe journal of allergy and clinical immunology. Global2026-11-15

Usability of Turbuhaler devices for children aged 5 to 11 years with asthma: A STep-wise Anti-inflammatory Reliever Therapy Children's Asthma Research substudy.

Biggs Rowan R, Barry Tasmin T, Oldfield Karen K, Clarke Amanda A et al.

Dry powder inhalers (DPIs) are an effective delivery system for asthma medications in children, yet global practice relies on the use of metered-dose inhalers, which have a greater environmental impact. A key issue relevant to implementation in clinical practice is whether children can master the technique and inspiratory flow required to use DPIs. We aimed to assess the ability of children aged 5 to 11 years with asthma to use the Turbuhaler DPI. Satisfactory Turbuhaler performance was assessed as part of the STep-wise Anti-inflammatory Reliever Therapy Children's Asthma Research study. This was assessed in the following 2 parts: an inspiratory flow rate assessment and the ability to perform all key steps using a dummy Turbuhaler DPI. The data from the first 100 children enrolled across 2 sites were used for this substudy. Of the 100 participants, only 1 had unsatisfactory inspiratory flow assessment at their first visit. All other participants achieved satisfactory performance for both inspiratory flow and the Turbuhaler technique. All mandatory steps of the dummy Turbuhaler technique were achieved by 13% of participants on their very first attempt; however, this increased substantially across subsequent attempts and visits. Satisfactory inspiratory flow rates were achieved by 93% of children on their very first attempt. With repeated training, almost all children aged 5 to 11 years can correctly use a Turbuhaler DPI device and achieve satisfactory inspiratory flow when clinically stable. It is important that children have their DPI technique checked and corrected at each asthma review following initial training.

PMID 43032436
阅读全文 →
PubMedAnnals of biomedical engineering2026-11-15

An Oscillometric Readout Assessing the Degree of Airway Smooth Muscle Activation In Vivo.

Henry Cyndi C, Boulay Marie-Ève MÈ, Côté Andréanne A, Bossé Ynuk Y

Oscillometry is a technique for probing respiratory mechanics that is emerging in clinical settings. One advantage of oscillometry that has yet to be fully exploited is its fine temporal resolution, which makes it suitable for capturing changes in lung mechanics that occur over short timescales, such as those caused by a deep inspiration (DI) or by airway smooth muscle. Herein, we hypothesized that the short-lived decrease in respiratory system resistance at 5 Hz (Rrs5) induced by a DI is attributable to airway smooth muscle. We assessed, for the first time, the temporal response to DI following administration of the bronchodilator salbutamol to confirm that the DI-induced decrease in Rrs5 is mediated by airway smooth muscle. Thirty-seven very mild-to-mild asthmatics underwent oscillometry before, during, and after a DI, both before and after the inhalation of salbutamol (200 µg). Rrs5 pre-DI and during the first tidal breath post-DI was compared to quantify the DI response. Rrs5 decreased by 12.7 ± 19.8% in response to DI, and this response was virtually abolished by salbutamol (p = 0.001). The DI response also correlated with the response to salbutamol (r = 0.47, p = 0.003). These results indicate that the temporary decrease in Rrs5 caused by DI is attributable to airway smooth muscle. This change in Rrs5 pre versus post-DI is readily measured, and its magnitude is likely to reflect the degree of airway smooth muscle activation. It holds the potential to aid in the diagnosis of asthma and in predicting responses to bronchodilator drugs.

PMID 43034933
阅读全文 →
PubMedPediatric pulmonology2026-11-13

Clinical Outcomes and Resource Utilization Over 10 Years of Institutional Treatment Practice Changes in Pediatric Asthma Exacerbations.

Kaewwaew Dokfai D, Anuntaseree Wanaporn W, Ruangnapa Kanokpan K, Saelim Kantara K et al.

To evaluate changes in clinical outcomes and resource utilization associated with changes in institutional practice for the management of acute asthma exacerbations in children over a 10-year study period. This retrospective cohort study included children aged 2-15 years hospitalized for moderate-to-severe asthma exacerbations from 2016 to 2025 (n = 329). Patients were categorized according to the institutional treatment strategy implemented during different periods of the study; conventional oxygen therapy with bronchodilator delivery using a jet nebulizer (JN group), n = 196), high flow nasal cannula oxygen therapy with bronchodilator via JN (HFNC-JN group; n = 80), and HFNC with an in-line vibrating mesh nebulizer (HFNC-VN group; n = 53). Inverse probability of treatment weighting was used to adjust for baseline differences among the groups. The median hospital length of stay differed significantly among the JN, HFNC-JN, and HFNC-VN groups: 59 (interquartile range [IQR], 44, 71), 64 (IQR, 55, 91), and 78 (IQR, 55, 101) h, respectively (p < 0.001). The corresponding percent change in respiratory rate at 24 h differed significantly: -12.5% (IQR, -22.2%, -4.9%), -22.2% (IQR, -31.0%, 0.0%), and -19.6% (IQR, -29.4%, -10.8%) (p = 0.038). The HFNC-VN group received higher cumulative salbutamol doses at 1, 6, 12, 24, and 48 h and incurred the highest treatment costs. Changes in institutional treatment practices for asthma exacerbation, including oxygen therapy, respiratory support, bronchodilator administration, and weaning practices, were associated with longer hospital stays and higher total treatment costs. These findings provide real-world evidence supporting the need for standardized treatment practices and development of evidence-based treatment protocols.

PMID 43024401
阅读全文 →
PubMedCureus2026-11-09

Mycoplasma pneumoniae Infection Associated With a Severe Asthma Exacerbation in a Five-Year-Old Child: A Case Report.

Yahia Asmae A, Alaoui-Inboui Fatima Zahra FZ, Ahmito Othmane O, Chbani Kamilia K et al.

Mycoplasma pneumoniae is a recognized respiratory pathogen in children and may act as a trigger for acute asthma exacerbations. We report the case of a five-year-old child with known asthma and Down syndrome who was admitted with a severe asthma exacerbation associated with marked respiratory distress and hypoxemia. Initial treatment included inhaled salbutamol, systemic corticosteroids, oxygen support, and empirical antibiotic therapy with amoxicillin, but the clinical response was slow, with persistent fever and hypoxemia. Multiplex respiratory polymerase chain reaction (PCR) testing of a nasopharyngeal sample identified M. pneumoniae. A macrolide was subsequently introduced, and clinical improvement was observed thereafter, alongside continued standard asthma therapy, with resolution of respiratory distress, normalization of pulmonary auscultation, and recovery of oxygen saturation on room air. The present case highlights the importance of considering M. pneumoniae in severe or unusually prolonged asthma exacerbations, particularly when fever and hypoxemia persist despite standard asthma management.

PMID 43001192
阅读全文 →
PubMedBiochemical pharmacology2026-11-06

Probenecid promotes relaxation and potentiates the effects of cyclic nucleotide-elevating agents in the pig detrusor.

Leonardi Guilherme Ruiz GR, Moretti Mariana Burille MB, Toledo Tatiana Alves TA, da Costa Jose Luiz JL et al.

Probenecid is a uricosuric agent also used as an antibiotic adjuvant. It inhibits, organic acid transporters (OATs), multidrug resistance-associated proteins (MRPs) and pannexin-1 (Panx-1) channels and activates transient receptor potential vanilloid 2. We hypothesized that probenecid could modulate detrusor smooth muscle reactivity, either alone or in combination with relaxant agents. Functional, biochemical, and immunohistochemical approaches were employed. The relaxant effects of probenecid (1 nM-1 mM) were assessed in isolated pig detrusor alone and in combination with inhibitors or antagonists. The effects of probenecid preincubation (0.1, 0.3, and 1 mM) on relaxations induced by cAMP- or cGMP-elevating agents were also evaluated. Probenecid produced concentration-dependent relaxation with a maximal response of 56% and potentiated the relaxations induced by salbutamol, forskolin, riociguat, cilostazol, and tadalafil. Potentiation of salbutamol- and tadalafil-induced relaxations was prevented by the soluble guanylyl cyclase (sGC) inhibitor, ODQ. In detrusor stimulated with sGC modulators, probenecid increased intracellular and reduced extracellular cGMP levels, whereas the cAMP levels were unaffected. Selective pharmacological tools targeting OAT, P2X7, and Panx-1 did not reproduce the potentiating effects of probenecid. Immunofluorescence revealed PDE3A, PDE5, and MRP4 expression in the urothelium, lamina propria, and smooth muscle, with the highest intensity in the urothelium. In conclusion, probenecid potentiates detrusor relaxation, an effect associated with an increased intracellular-to-extracellular cGMP ratio. These findings support further investigation of probenecid, alone or combined with clinically approved agents such as tadalafil or cilostazol, as a potential therapeutic approach for overactive bladder dysfunction.

PMID 42994566
阅读全文 →

注册免费账户还可查看另外 9043 篇文献

免费注册查看全部文献 →

了解更多salbutamol